Rating Change
Benchmark reiterated its Speculative Buy rating on Harvard Bioscience, Inc. (NASDAQ:HBIO) on August 12, 2026.
reiterateNASDAQ:HBIO
Benchmark Reiterates Speculative Buy Rating on Harvard Bioscience, Inc. (HBIO)
Benchmark reiterated its Speculative Buy rating on Harvard Bioscience, Inc. (NASDAQ:HBIO) on August 12, 2026.
At publication ·
What changed
Harvard Bioscience, Inc. (NASDAQ:HBIO) · reiterate
- Firm
- Benchmark
- Rating
- Speculative Buy to Speculative Buy
- Price at event
- $6.17
- Market capitalization
- $33.5M
At a glance
Key takeaways
- Benchmark reiterated a Speculative Buy rating on Harvard Bioscience (HBIO) on August 12, 2026, with the stock trading at $6.17 and a market capitalization of $33.5 million.
Market Context
Harvard Bioscience, Inc. operates in the Healthcare sector. The stock currently trades at $6.17 with a market capitalization of $33.5M.
Analyst coverage from Benchmark provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Harvard Bioscience, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Harvard Bioscience, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Benchmark | Speculative Buy | N/A |
| Mar 16, 2026 | Benchmark | Speculative Buy | N/A |
| Mar 13, 2026 | Benchmark | Speculative Buy | N/A |
| Sep 10, 2025 | Benchmark | Speculative Buy | N/A |
| May 13, 2025 | Benchmark | Speculative Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View HBIO Stock Page
Frequently Asked Questions
What does the Speculative Buy rating mean for HBIO?
A rating of Speculative Buy from Benchmark reflects the analyst's outlook on Harvard Bioscience, Inc. (NASDAQ:HBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the HBIO forecast page.